Evidence supporting the use of: Bifidobacterium longum
For the health condition: Celiac Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bifidobacterium longum has been investigated as a potential adjunct in the management of Celiac Disease, but the evidence remains preliminary. Celiac Disease is characterized by an immune reaction to gluten that leads to intestinal inflammation and gut dysbiosis. Several studies have shown that individuals with Celiac Disease often present with reduced levels of beneficial gut bacteria, including Bifidobacterium species, and an increase in pathogenic bacteria. Research in vitro and in animal models suggests that B. longum may help modulate immune responses, decrease pro-inflammatory cytokines, and improve intestinal barrier function. A few small human studies and pilot trials have explored the effects of B. longum supplementation (alone or in combination with other probiotics) in children and adults with Celiac Disease. These studies have reported some improvements in gut microbiota balance, decreased markers of inflammation, and mild symptom relief. However, sample sizes have been small, study durations short, and outcomes variable. There is not yet strong evidence that B. longum can replace a gluten-free diet or significantly alter disease progression. Clinical guidelines do not currently recommend probiotics as standard therapy for Celiac Disease. In summary, there is emerging scientific interest and some early clinical data supporting the potential adjunctive use of B. longum in Celiac Disease, but robust, large-scale clinical trials are needed to establish clear efficacy and recommendations.

More about bifidobacterium longum
More about Celiac Disease